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Graphical Abstract 
 
Abstract 
Inflammation after joint injury leads to responses that result in eventual osteoarthritis development. 
Blockade of inflammation, by suppressing NF-kB expression, has been shown to reduce joint injury-
induced chondrocyte apoptosis and reactive synovitis in vivo. Herein, we demonstrate that the 
suppression of NF-kB p65 expression also significantly mitigates the acute pain sensitivity induced by 
mechanical injury to the joint. These results suggest that early intervention with anti-NF-kB 
nanotherapy mitigates both structural and pain-related outcomes, which in turn may impact the 
progression of post-traumatic osteoarthritis. 
 
Purpose and Rationale 
The goal of this study is to evaluate pain-
related outcome following nanotherapy, as pain 
represents the most common symptom in post-
traumatic osteoarthritis but the least monitored 
outcome in preclinical studies.  
Introduction 
Post-traumatic osteoarthritis (PTOA) is a 
form of osteoarthritis (OA) that develops after 
a joint injury and in which the nature and time 
of trauma is generally known. PTOA accounts 
for 12% of all OA but the true incidence may 
be higher given the long delay between injury 
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and PTOA [1]. Studies have documented a 
robust inflammatory response in the immediate 
aftermath of joint injury that persists for months 
to years [2] and this inflammation likely 
contributes to sequelae of responses post-
injury. While pain is the most common 
symptom of patients seeking medical 
consultation, it is one of the least monitored 
outcomes in preclinical studies of PTOA. 
Furthermore, current treatment options focus 
on treating the clinical symptoms and are 
limited to analgesics and anti-inflammatory 
drugs, which have so far shown no disease-
modifying effects [2].  
NF-kB is a signaling pathway that controls 
gene products involved in a myriad of cellular 
responses including inflammation. Using a 
murine model of noninvasive controlled 
injurious compressions of the knee joint that 
allows the examination of cartilage responses at 
specific time points after trauma [3], we 
previously showed that intra-articular (IA) 
delivery immediately after injury of a 
nanoparticle (NP) comprising a peptide, 
p5RHH complexed to siRNA suppressing NF-
kB p65 expression significantly reduced two 
important early events: chondrocyte apoptosis 
and synovial inflammation [4]. The goal of the 
present study was to investigate whether NP-
based suppression of NF-kB expression in the 
joint also reduces injury-induced pain in mice.  
Materials and Methods 
p5RHH-siRNA NP Preparation 
p5RHH-siRNA NP was prepared as 
previously described [4]: p5RHH peptide 
(synthesized by GenScript) was dissolved at 10 
mM in DNAse-, RNAse-, and protease-free 
sterile purified water (Cellgro) and stored in 10 
μl aliquots at −80°C before use. p65 siRNA 
(Sigma-Aldrich) was dissolved at 100 μM in 1× 
siRNA buffer (Thermo Scientific) and stored in 
10-μl aliquots at −80°C before use. NPs were 
prepared by mixing equal volumes of the 
p5RHH peptide and siRNA at a peptide:siRNA 
ratio of 100:1 in HBSS with Ca2+ and Mg2+ 
(Gibco, Life Technologies) and incubated at 
37ºC for 40 minutes and then stabilized with 
albumin at final siRNA concentration of 500 
nM before IA injection. This preparation 
typically results in a nominal NP size of ~ 55 
nm after albumin coating, as measured by 
atomic force microscopy and dynamic light 
scattering, and zeta potentials varying from +12 
to −5.5 mV and polydispersity index varying 
from 0.120 to 0.190 depending on size and the 
presence or absence of the exogenously applied 
albumin coating [5; 6]. 
Animals 
All animal experiments were performed in 
compliance with federal laws and in strict 
accordance with the guidelines established by 
the Division of Comparative Medicine at 
Washington University. The animal protocol is 
subjected to annual review and approval by 
Institutional Animal Care and Use Committee 
of Washington University. 
Noninvasive Mechanical Injury Model 
Experiments were performed on 10- to 12-
week-old male C57BL/6J mice (The Jackson 
Laboratory, Maine) using a materials testing 
machine (Instron ElectroPuls E1000) as 
previously described [4]. In brief, mice were 
anesthetized and subjected to cyclic axial 
compressive loads applied to the right knee 
joint, with loads transmitted through natural 
joint articulations. Compressive loads were 
applied at 6 Newtons (N) for 0.34 seconds with 
a rise and fall time each of 0.17 seconds and a 
baseline hold time of 10 seconds between 
cycles for 60 cycles. The uninjured left knees 
were used as controls. After loading, all the 
mice were immediately administered 0.5 mg/kg 
buprenorphine-SR once IA as per protocol, to 
control pain for the first 72 hours.  
NP Administration 
On day 0, immediately after loading, the right 
knee was shaved and the skin was scrubbed 
with betadine prior to IA injection. The right 
knee was kept in a flexed position and volume 
of 15 μL of albumin-coated p5RHH-p65 
siRNA NP (0.1 μg siRNA, equivalent to siRNA 
at 7.5 × 10−12 mol) or p5RHH-scrambled 
siRNA NP (at the same volume and dose) or 
HBSS (15 μL) was administered IA using a 30-
gauge needle. The IA injections were repeated 
on days 1 and 2 (for a total of 3 doses). The left 
knees served as non-injured controls. We have 
previously shown that the articular dwelling 
time of NP exceeded 48 hours although the 
beneficial effects persisted at least 2 weeks in 
this model [4]. 
Pain Assessment 
Pain was assessed weekly after loading, up to 
21 days using a Small animal ALGOmeter 
(SMALGO), a pressure-based analgesimeter 
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for easy assessment of pain sensitivity 
threshold of the animal when applying a 
progressive force over the relevant location 
(knee) on the animal. The stimulation was 
increased until a reaction (shudder or 
vocalization) from the animal was obtained. 
The maximum force was then automatically 
recorded and analyzed. The operator was 
blinded to the treatment administered.  
Statistics 
Comparisons between multiple groups (≥ 3) 
were performed by one-way ANOVA and 
Bonferroni’s correction for multiple 
comparisons was performed. P < 0.05 between 
experimental groups was considered 
significant.  
Results  
We assessed pain threshold sensitivity 
following NP treatment using SMALGO. We 
found that mice treated with p5RHH-p65 
siRNA NP maintained pain threshold while 
animals treated with HBSS or p5RHH-
scrambled siRNA NP showed significantly 
reduced pain threshold (Fig. 1).  
 
Figure 1. p5RHH-p65 siRNA nanotherapy suppresses pain after joint injury in mice. Mice were subjected to compression 
injury (6 N) and treated IA with HBSS, 0.1 µg of p5RHH-p65 or scrambled (scram) siRNA NP (in 15 µL volume) immediately 
following loading, and again on days 1 and 2 (3×). Threshold sensitivity was assessed by Small animal ALGOmeter on the 
indicated days. Pain threshold is expressed as the ratio of injured knee/contralateral control knee. Baseline ratio = 1.0. 
Untreated (HBSS) and scram siRNA NP-treated mice showed significantly reduced threshold. N = 5 per group.  
The attenuating effect observed with p65 
suppression lasted at least 21 days after 
initiation of nanotherapy. These are the first 
reported outcomes showing mitigation of pain 
sensitivity following NF-kB suppression in a 
model of joint injury. While this study provides 
solid data on pain mitigation in the first 3 weeks 
post-joint injury, further studies would 
determine dose-response relationship and the 
time course of therapeutic efficacy with the 
development of PTOA in this model.  
Discussion 
Although the involvement of inflammatory 
responses in the promotion of cartilage 
catabolism post-joint injury has been 
extensively studied [2], it remains to be 
determined whether antagonism of 
inflammation will also improve pain-related 
outcomes. Indeed, IA administration of IL-1 
receptor antagonist exhibits structural disease-
modifying effects in a rodent model of PTOA 
[7]. However, in clinical studies, the 
administration of commercially available IL-
1ra had no effect in fully established knee OA 
[8] and only offered short-term (2 weeks) 
improvement in pain and function when 
administered within the first month following 
knee injury (NCT00332254) [9]. Early anti-
inflammatory intervention has been attempted 
with broad-spectrum anti-inflammatory drugs 
such as corticosteroids. A recent study suggests 
that shutting down early inflammation with 
dexamethasone in a rabbit PTOA-like model 
has lasting effect in ameliorating histological 
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cartilage grade but afforded no protection 
against long-term structural damage [10]. 
Clinical trials (NCT01692756 and 
NCT02318433) have been initiated to examine 
the effects of early anti-inflammatory 
intervention in joint injury, the results of which 
are not yet available.  
Conclusion 
These findings from this study corroborate our previous observations and provide further rationale for 
targeting NF-kB, not only to mitigate cartilage degeneration and synovial inflammation but also 
functional outcomes of the inflammatory processes in PTOA. 
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